Jul 29, 2021 17:34 JST

Source: Eisai

Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment

TOKYO, Jul 29, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate the global standard factors of environmental, social and governance (ESG) into their investment decisions. Eisai received particularly high scores in "Corporate Governance", "Human Rights & Community", "Labor Standards", and "Anti-Corruption", among others. As of the end of June 2021, a total of 1,045 companies from around the world have been selected for the FTSE4Good Developed Index, including 204 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index, and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Join The Global Environmental Initiative "RE100"
September 14 2021 16:46 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
September 14 2021 11:36 JST
 
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"
September 13 2021 15:37 JST
 
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
August 31 2021 08:42 JST
 
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma
August 16 2021 09:07 JST
 
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)
August 12 2021 08:31 JST
 
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
August 05 2021 10:45 JST
 
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures
August 02 2021 11:24 JST
 
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
July 30 2021 09:07 JST
 
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021
July 30 2021 08:24 JST
 
More Press release >>

Latest Press Release


More Latest Release >>